
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna is forecasting product sales of $1.73 billion in 2025, with an anticipated increase to $2.15 billion in 2026, signifying strong revenue growth potential. The company's recent $1.5 billion debt deal enhances its balance sheet and provides flexibility for managing uncertainties while capitalizing on future opportunities, illustrating financial prudence. Additionally, improvements in manufacturing efficiency are projected to expand gross margins by 10% over the next three years, underscoring the company’s ability to recover from previous gross margin compressions.
Bears say
The financial analysis reveals a negative outlook for Moderna's stock, primarily due to a significant reduction in COVID vaccine sales, which are projected to decline from $18 billion in 2022 to $6.7 billion in 2023, further impacted by waning vaccination rates. The company faces competitive pressures in the respiratory vaccine space, particularly with established products like Arexvy and Abrysvo, leading to a lowered long-term revenue projection for COVID-related sales from $3.5 billion to $2.5 billion annually. Additionally, Moderna's negotiating position in the European market appears weak, anticipating low sales for both 2024 and 2025, contributing to an overall decrease in its projected enterprise value from $22.12 billion to $21.53 billion.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares